The company has received an official grant of patent from the European Patent Office, EPO regarding the company’s broadened patent application for stimulation of hair growth.
The official grant follows the “Intention to Grant” which was communicated on November 21, 2018.
With EPO’s grant of patent no. EP 3087999 B1, there is now broad protection for Follicum’s peptides in Europe until 2032.
A broader protection
The patent that protects the company’s peptides generally as a product, and for the stimulation of hair growth specifically, is a broadening of the previously granted, first patent on FOL-005. The patent covers the drug candidate FOL-005 and related substances. As previously communicated, Follicum has also filed a patent application for a new formulation, something which can provide extended protection for FOL-005 for an additional 8 years.
“With this grant, we get a broader protection for our lead candidate. Europe is a very important market and the official grant is of great importance to us. Thanks to the patent, we can continue to run the hair project without the risk of competition. Follicum continues to work to broaden and extend its patent portfolio and this grant is welcome news,” says Jan Alenfall, CEO, Follicum.